Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX Laboratories reports a 3% revenue increase to $638 million for Q2 2020, with 4% organic growth, bolstered by a 7% rise in Companion Animal Group (CAG) Diagnostics. EPS rose 20% to $1.72, reflecting effective cost control and operational efficiency. However, new CAG instrument placements and Water business revenues faced declines due to COVID-19 impacts. Notable growth in CAG diagnostics was observed, supported by improved clinical visit trends. The company has suspended full-year guidance amid ongoing pandemic uncertainty.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will release its second-quarter financial results for 2020 on July 31, 2020, before market opening. The company will hold an analyst conference call at 8:30 a.m. ET, accessible via a webcast on their website. A virtual Investor Day is scheduled for August 13, 2020, from 10:00 a.m. to 12:00 p.m. ET, with a replay available post-event. IDEXX, a leader in veterinary diagnostics, employs over 9,000 people and serves customers in over 175 countries.